MedAdvisor Asthma Link

Listed medication adherence specialist MedAdvisor yesterday announced a new 12 month pact with Asthma Australia, with the aim of improving health outcomes for the estimated 2.4 million Australians living with asthma.  The company said it already has more than 45,000 users with asthma using the platform to manage their regular prescriptions.

“MedAdvisor data shows patients living with asthma and utilising MedAdvisor are up to 30% more adherent to their preventer medication than those not using the platform,” the company said.  “MedAdvisor and Asthma Australia have a shared vision to reduce the health, social and economic impacts of chronic diseases,” said MedAdvisor CEO Robert Read.

“Asthma Australia will help MedAdvisor bring awareness that world leading medication management programs exist,” he added, with the partnership an “important part of the company’s user acquisition strategy”. 

The asthma partnership complements similar arrangements with other groups including Epilepsy Queensland, Diabetes Australia, Painaustralia, Glaucoma Australia & Osteoporosis Australia.  Industry companies on board include BUPA, Bristol-Myers Squibb Australia, AstraZeneca, Novartis, GlaxoSmithKline Australia, UCB, Arrow Pharmaceuticals and Apotex.

Learn more about MedAdvisor in the education module below.

Source:pharmacydaily.com.au, Wednesday 30 November 2016